CJC-1295 No DAC Ipamorelin Blend Peptide For Sale
CJC-1295 No DAC Ipamorelin research peptide for sale: 10mg, 5mg sizes with discount code. USA sources cheapest: cost per month, price per vial or cost per mg.
Search for CJC-1295 No DAC/Ipamorelin Blend research peptides for sale: 10mg, 20mg and more vial sizes. Sort by cost per month, price per vial or cost per mg with COAs to buy from USA sources.
How much does CJC-1295 No DAC/Ipamorelin Blend cost per month?
An illustrative CJC-1295 No DAC/Ipamorelin Blend cost model works out to about $26.52 per month: Ascension Peptides's listed 10 mg purchase quantity at $35.00 with code WPA, divided into 0.25 mg amounts daily. This quantity provides 40.0 nominal portions — about 5.7 weeks at the selected cadence, before preparation losses or stability limits — for roughly $6.13 per week or $26.52 per 4.33-week month. Vial count and milligrams per vial must be checked separately. This is illustrative arithmetic combining independently selected lifetime modal inputs, not a verified most-common joint protocol. The amount distribution includes 11,214 calculator runs; overall cadence comes from 3,608 separate lifetime frequency responses across amounts. Calculator inputs are not confirmed administration or recommendations.
Use the live cost-per-month card to change nominal purchase quantity, amount, cadence and vendor strategy. Recorded purity can be compared separately; it is not independent verification or a quality guarantee. Confirm package composition and checkout price with the vendor.
About CJC-1295 No DAC/Ipamorelin Blend
Pre-clinical / research-onlyAlso known as: CJC-1295 (Mod GRF 1-29) + Ipamorelin · GHRP/GHRH blendThis blend pairs CJC-1295 without DAC (Mod GRF 1-29) with ipamorelin, and is one of the most-sourced growth-hormone-axis research combinations. It ships as a co-lyophilized powder reconstituted with bacteriostatic water before use.[1]
What to check before you buy CJC-1295 No DAC/Ipamorelin Blend:
- A third-party COA confirming the purity (ideally ≥98% by HPLC) and identity of BOTH peptides, not just one — blends are where vague single-line "tested" claims hide the most.
- A stated CJC-1295-to-ipamorelin ratio and per-vial amounts, with a COA dated within the last 6–12 months for the batch you are buying.
- Accurate total fill matching the label. Mislabeled ratios or under-filled blend vials are a common failure mode and make dosing each component impossible to calculate.
Published research is limited to the parent peptides individually — a Phase 1 study of CJC-1295 no-DAC in healthy adults (Teichman et al., JCEM 2006) documented dose-dependent IGF-1 elevation,[2] and ipamorelin was characterized for GH selectivity by Raun et al. (Eur J Endocrinol 1998).[3] No published trials evaluate the combination as a fixed-ratio research blend.
Regulatory: Neither component is FDA-approved. CJC-1295 and ipamorelin both appear on the FDA 503A "do not compound" interest list (2023). Research-only material.
CJC-1295 No DAC/Ipamorelin Blend: Mechanisms, Half-Life & Research Data
A skimmable deep dive into how CJC-1295 No DAC/Ipamorelin Blend works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.
How it works
The blend pairs two pulsatile growth-hormone-axis tools that act on different receptors. CJC-1295 without DAC — also known as Mod GRF 1-29 — is a tetra-substituted analog of the 29-amino-acid N-terminal active fragment of human growth-hormone-releasing hormone (GHRH); the four substitutions resist DPP-4 cleavage and extend the half-life from a few minutes (native GHRH) to roughly 30 minutes, but, critically, do not include the drug-affinity-complex (DAC) maleimide that binds albumin in the DAC variant.[2][4] The peptide acts on the GHRH receptor on pituitary somatotrophs, increasing the amplitude of the next endogenous GH pulse rather than producing a sustained GH elevation.[8] Ipamorelin is a selective pentapeptide ghrelin-receptor (GHS-R1a) agonist that drives GH release through a parallel pathway, with minimal cortisol, prolactin, or aldosterone elevation relative to other GHRPs.[1] Using the two together is intended to amplify pulse amplitude while preserving the circadian GH rhythm and the hypothalamic somatostatin feedback loop, in contrast to recombinant human GH which abolishes endogenous pulsatility.[6][7]
Active research areas
- Pituitary GH and IGF-1 elevationThe strongest direct human evidence is the Phase 1 program for CJC-1295 with DAC in healthy adults, which documented dose-dependent IGF-1 elevation over 5–8 days per dose.[2] The Phase 1 program for the no-DAC molecule is less extensively published; investigators are interested in whether short-acting CJC + ipamorelin produces meaningful clinical benefit at the lower per-dose IGF-1 exposures generally seen with the no-DAC formulation.
- Adult growth hormone deficiencyCJC-1295 (DAC and no-DAC) and ipamorelin were both developed under growth-hormone-deficiency programs that did not advance to Phase 3 approval.[5] Investigator-initiated work in adult GHD continues to ask whether GHRH-analog + GHRP combinations are a less-suppressive alternative to recombinant hGH.[7]
- Post-operative ileus (ipamorelin program)
- 503A compounding statusIn September 2023 the FDA placed both CJC-1295 and ipamorelin on its 503A interest list (Category 2), citing absence of human safety data and unresolved peptide-identity questions;[3] the practical effect is that 503A compounding pharmacies in the United States cannot legally compound either component (or the blend) for patient use.[7]
Open questions & leading hypotheses (2)
- Hypothesis: The GHRH-analog + GHRP combination produces clinically meaningful benefit beyond what either component achieves alone.Evidence: Mechanistically the rationale is clean: the two molecules engage parallel receptors, and animal and small human pharmacodynamic studies report higher GH peaks for the combination than for either component alone.[1][2][8] Counter-evidence: no controlled trial has measured patient-relevant endpoints (body composition, sleep quality, recovery from soft-tissue injury, IGF-1 sustained over months) for the fixed-ratio blend specifically, and the no-DAC formulation has not been characterised pharmacokinetically to the same depth as the DAC variant.[4]
- Hypothesis: Preserving pulsatile GH release is meaningfully safer or more physiologic than recombinant hGH replacement.Evidence: Ionescu and Frohman documented that pulsatile GH secretion persists during continuous CJC-1295 stimulation, supporting the pulsatility-preservation framing.[8] Counter-evidence: the long-term safety profile of GHRH + GHRP combinations in adults has not been characterised in any Phase 3 trial, and the regulatory bin (FDA 503A Category 2) reflects exactly this evidentiary gap.[3][7]
What community users report
Anecdotal — not controlled-trial evidence
Across r/Peptides and r/PeptideAdmin, users most often run CJC-1295 no-DAC + ipamorelin as a 100 mcg + 100–300 mcg subcutaneous dose taken once or twice daily on an empty stomach, with anecdotal reports of deeper sleep within the first one to two weeks, improved skin and nail quality over the first month, and modest body-composition shifts over multi-month cycles.[9][10] A subset describes water retention, transient flushing, or numbness/tingling shortly after injection; many users explicitly choose the no-DAC variant over CJC-1295 DAC on the rationale that the shorter half-life produces a more pulse-like GH response rather than a sustained elevation. **These reports are anecdotal and have not been validated in controlled trials.** They are useful for understanding what people who have already chosen to use the blend are experiencing, but they do not establish that any specific dose, schedule, or duration is safe or effective.
Sources & references (10)
Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.
- [1]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998;139:552–561. · PMID: 9849822 link
- [2]Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. JCEM 2006;91:799–805. · PMID: 16352683 link
- [3]FDA 503A Bulks List — CJC-1295 and ipamorelin entries, Sep 2023 link
- [4]Sackmann-Sala L et al. A comparison of CJC-1295 with and without drug affinity complex (DAC) on growth-hormone pulsatility — review of pharmacokinetic differences between the two CJC-1295 formulations. Endocr Rev 2015;36(suppl):SAT-291. link
- [5]ClinicalTrials.gov: NCT00104897 — Phase 1/2 study of CJC-1295 (drug affinity complex form) in adult growth hormone deficiency, ConjuChem. link
- [6]Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? — context for GHRH-analog dosing relevant to the CJC-1295 no-DAC molecule. Clin Interv Aging 2006;1:307–308. · PMID: 18046908 link
- [7]Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev 2018;6:45–53 — review covering GHRH analogs and ghrelin mimetics including CJC-1295 and ipamorelin. · PMID: 28526632 link
- [8]Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. JCEM 2006;91:4792–4797 — pulsatility-preservation evidence used to frame the CJC + GHRP combination logic. · PMID: 16940451 link
- [9]Community report — r/Peptides CJC-1295 / Ipamorelin combination dosing threads (subreddit), accessed May 2026. link
- [10]Community report — r/PeptideAdmin CJC + Ipa protocol discussions (subreddit), accessed May 2026. link
What CJC-1295 No DAC/Ipamorelin Blend Costs Right Now
WPA currently tracks CJC-1295 No DAC/Ipamorelin Blend from 13 distinct vendors. In-stock CJC-1295 No DAC/Ipamorelin Blend vials run from $35 to $94.49 — a 2.7x spread for the same compound. Ascension Peptides holds the lowest sticker price at $35. Normalized to milligrams, CJC-1295 No DAC/Ipamorelin Blend costs $3.50/mg to $9.45/mg on this page. The best per-milligram value is the listed 10 mg purchase quantity from Ascension Peptides.
CJC-1295 No DAC/Ipamorelin Blend is stocked in 2 sizes: 10 mg listed quantity; vial count not recorded; 20 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.
Ranked by true cost per milligram, the CJC-1295 No DAC/Ipamorelin Blend listings WPA tracks are: Ascension Peptides — 10mg at $35 ($3.50/mg), COA purity 99.75%; Southern Aminos — 20mg at $71.40 ($3.57/mg), COA purity 99.83%; Modified Aminos — 10mg at $35.99 ($3.60/mg), COA purity 99.00%; EZ Peptides — 10mg at $47.70 ($4.77/mg); Ameano Peptides — 10mg at $47.70 ($4.77/mg).
CJC-1295 No DAC/Ipamorelin Blend COA Coverage Across Tracked Vendors
12 of the 13 tracked CJC-1295 No DAC/Ipamorelin Blend listings (92%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 10 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 99.00% to 99.96%. 10 listings record more CJC-1295 No DAC/Ipamorelin Blend in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 10/26.
To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the CJC-1295 No DAC/Ipamorelin Blend offer. WPA's listing fields do not establish that a report was independently verified.
CJC-1295 No DAC/Ipamorelin Blend Calculator Input Observations
In lifetime CJC-1295 No DAC/Ipamorelin Blend calculator inputs, 250mcg is the most frequent entered amount (2,110 of 11,214 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (1,122 of 3,607 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 250mcg, Daily (7x/wk) is most frequent (243 of 722 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 20 mg of listed product divided by 0.25 mg gives roughly 80 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.
CJC-1295 No DAC/Ipamorelin Blend Discount Codes
13 of the 13 tracked CJC-1295 No DAC/Ipamorelin Blend listings carry a WPA researcher discount code. The largest live discount is 50% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.
About CJC-1295 No DAC/Ipamorelin Blend
This blend pairs CJC-1295 without DAC (Mod GRF 1-29) with ipamorelin, and is one of the most-sourced growth-hormone-axis research combinations. It ships as a co-lyophilized powder reconstituted with bacteriostatic water before use.
CJC-1295 No DAC/Ipamorelin Blend is a blend of CJC-1295 (no DAC) and Ipamorelin, so a COA has to confirm each component separately — a single purity figure for the mixture is not enough. Its reported half-life is ~30 min (CJC) and ~2 hr (Ipamorelin). Calculator inputs do not establish why a cadence was selected or validate a protocol. Neither component is FDA-approved.
How to Read the CJC-1295 No DAC/Ipamorelin Blend Comparison
- Price per milligram — Every CJC-1295 No DAC/Ipamorelin Blend listing is normalized to $3.50/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
- COA metadata and purity — 12 CJC-1295 No DAC/Ipamorelin Blend listings are marked for COA availability, and 10 have a recorded purity value. These fields do not independently verify a report.
- Vials sizes — The CJC-1295 No DAC/Ipamorelin Blend comparison includes 10mg and 20mg listed purchase quantities. Check package composition separately.
- Stock status — Live in-stock state for each CJC-1295 No DAC/Ipamorelin Blend listing, refreshed on a recurring basis.
Frequently Asked Questions: CJC-1295 No DAC/Ipamorelin Blend
Is it legal and safe to buy CJC-1295 No DAC/Ipamorelin Blend for research?
In the US, CJC-1295 No DAC/Ipamorelin Blend is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. Both peptides are research chemicals with no approved human form, and the pre-combined blend is sold for laboratory use only. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 13 CJC-1295 No DAC/Ipamorelin Blend listings from 13 vendors.
How do I verify a CJC-1295 No DAC/Ipamorelin Blend COA so I'm not getting an underdosed vial?
A Certificate of Analysis (COA) may report tests for a specific CJC-1295 No DAC/Ipamorelin Blend batch. Check that the report identifies the compound (both CJC-1295 (no DAC) and ipamorelin at the labeled ratio — not a DAC version or a single-peptide vial), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For CJC-1295 No DAC/Ipamorelin Blend specifically, 12 of 13 tracked listings (92%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 10 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 10/26.
Which CJC-1295 No DAC/Ipamorelin Blend vendor should I pick?
There's no single "best" CJC-1295 No DAC/Ipamorelin Blend vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. For a blend, COA identity matters double: a good vendor's COA confirms both peptides are present at the stated amounts, not just one of them. 13 vendors currently carry CJC-1295 No DAC/Ipamorelin Blend, and Ascension Peptides holds the best true value at $3.50/mg on the 10 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.
How much does CJC-1295 No DAC/Ipamorelin Blend cost — and how do I know I'm not overpaying?
Judge CJC-1295 No DAC/Ipamorelin Blend by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It is usually sold as a 5 mg + 5 mg (10 mg total) vial, and buying the two peptides pre-blended is normally cheaper than sourcing them separately. Tracked CJC-1295 No DAC/Ipamorelin Blend listings currently run $3.50/mg to $9.45/mg across 10mg, 20mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.
How much CJC-1295 No DAC/Ipamorelin Blend do I need for one full cycle?
In lifetime CJC-1295 No DAC/Ipamorelin Blend calculator inputs, 250mcg is the most frequent entered amount (2,110 of 11,214 runs). Separately, Daily (7x/wk) is the most frequent overall cadence (1,122 of 3,607 lifetime frequency responses, across entered amounts). Among lifetime frequency responses with amounts within ±8% of 250mcg, Daily (7x/wk) is most frequent (243 of 722 responses). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 20 mg purchase quantity by 0.25 mg gives roughly 80 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.
Are discount codes available for CJC-1295 No DAC/Ipamorelin Blend?
Participating CJC-1295 No DAC/Ipamorelin Blend vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 13 of the 13 tracked CJC-1295 No DAC/Ipamorelin Blend listings carry a code right now, the largest worth 50% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.
Lowest priced CJC-1295 No DAC/Ipamorelin Blend peptide for sale?
To surface the lowest priced CJC-1295 No DAC/Ipamorelin Blend for sale, WPA continuously compares 14 USA suppliers and 956 "for research" products, ranking every verified CJC-1295 No DAC/Ipamorelin Blend listing by true cost so the cheapest vials rise to the top. The lowest priced single CJC-1295 No DAC/Ipamorelin Blend vial currently starts at $35.00. We currently track 13 CJC-1295 No DAC/Ipamorelin Blend products in our system. Pricing is generally refreshed weekly as vendors update stock, prices, and discount codes.